Literature DB >> 11008194

Double blinded evaluation of the effects of pallidal and subthalamic nucleus stimulation on daytime activity in advanced Parkinson's disease.

.   

Abstract

The results of a double blinded evaluation of the effects of globus pallidus (GPi; n=7) and subthalamic nucleus (STN; n=11) stimulation in patients with advanced Parkinson's disease are summarized. The patients were evaluated at 6-8months after surgery. In order to determine the benefits afforded by the stimulation to the actual daily activities, the patients were maintained on-medication with optimal doses and schedules. The stimulation was turned off overnight for at least 12h. It was turned on in the morning (or maintained turned off), and the best and worst scores during daytime activity were recorded, as on-period and off-period scores, respectively. A reduction in total motor score on the Unified Parkinson's Disease Rating Scale was clearly elicited by GPi and STN stimulation at both the off-period (-57 and -29%, respectively) and the on-period (-36 and -25%, respectively). The difference in effects between GPi and STN stimulation appeared to be due largely to an unintended difference in the patients' preoperative symptoms. The benefits provided by stimulation to the actual daily activities appears to be limited in patients who have become unresponsive to a large dose of levodopa. Two advantages of GPi and STN stimulation were identified. Firstly, the stimulation can supplement a reduced action of levodopa during the off-period. It thus improves the patient's daily activities through attenuation of the motor fluctuations. Secondly, the stimulation can replace part of the action of levodopa during the on-period. It thus attenuates dopa-induced dyskinesia through a reduced dose of medication. More importantly, the stimulation improves the daily activities in dopa-intolerant patients who are being administered a small dose of levodopa because of unbearable side effects. In addition, GPi stimulation has its own inhibitory effect on dopa-induced dyskinesia. Clinically important improvement was observed in severe gait freezing in 2 patients following unilateral anterodorsal GPi stimulation on the right side alone.

Entities:  

Year:  2000        PMID: 11008194     DOI: 10.1016/s1353-8020(00)00046-8

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation.

Authors:  M C Rodriguez-Oroz; I Zamarbide; J Guridi; M R Palmero; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

2.  Comparison of Efficacy of Deep Brain Stimulation of Different Targets in Parkinson's Disease: A Network Meta-Analysis.

Authors:  Zhiqi Mao; Zhipei Ling; Longsheng Pan; Xin Xu; Zhiqiang Cui; Shuli Liang; Xinguang Yu
Journal:  Front Aging Neurosci       Date:  2019-02-22       Impact factor: 5.750

3.  Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson's Disease.

Authors:  Kazuhiro Samura; Yasushi Miyagi; Minako Kawaguchi; Fumiaki Yoshida; Tsuyoshi Okamoto; Masatou Kawashima
Journal:  Neurol Med Chir (Tokyo)       Date:  2019-06-21       Impact factor: 1.742

4.  Globus Pallidus Internus (GPi) Deep Brain Stimulation for Parkinson's Disease: Expert Review and Commentary.

Authors:  Ka Loong Kelvin Au; Joshua K Wong; Takashi Tsuboi; Robert S Eisinger; Kathryn Moore; Janine Lemos Melo Lobo Jofili Lopes; Marshall T Holland; Vanessa M Holanda; Zhongxing Peng-Chen; Addie Patterson; Kelly D Foote; Adolfo Ramirez-Zamora; Michael S Okun; Leonardo Almeida
Journal:  Neurol Ther       Date:  2020-11-02

5.  Deep brain stimulation of pallidal versus subthalamic for patients with Parkinson's disease: a meta-analysis of controlled clinical trials.

Authors:  Fan Xu; Wenbin Ma; Yongmin Huang; Zhihai Qiu; Lei Sun
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-22       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.